Methanol and Ethylene Glycol Poisoning

Methanol and ethylene glycol poisoning are critical toxicological emergencies that can lead to severe metabolic disturbances, end-organ damage, and death if not rapidly recognized and treated. Their clinical presentations are often similar, hinging on the conversion of relatively non-toxic parent alcohols into profoundly toxic metabolites. Mastering the pathophysiology, diagnostic clues, and specific antidotal therapy is essential for any clinician, as timely intervention can prevent irreversible blindness, renal failure, and fatal acidosis.

Pathophysiology: The Common Thread of Toxic Metabolism

Both methanol and ethylene glycol are themselves relatively benign central nervous system (CNS) depressants. The grave danger arises from their systematic metabolism by liver enzymes into acidic byproducts that ravage specific organ systems. This shared metabolic pathway is the key to understanding the poisoning timeline and the rationale for treatment.

The primary enzyme responsible is alcohol dehydrogenase (ADH), which initiates the conversion. For methanol, ADH oxidizes it to formaldehyde, which is then rapidly converted by aldehyde dehydrogenase to formic acid. Formic acid is the ultimate toxin; it inhibits mitochondrial cytochrome c oxidase, causing a profound metabolic acidosis and specifically damaging the optic nerve, leading to blurred vision, "snowfield" visual effects, and potential permanent blindness.

Ethylene glycol follows a parallel but distinct path. ADH oxidizes it to glycoaldehyde, which is then metabolized to glycolic acid and, most critically, oxalic acid. Glycolic acid is a major contributor to the severe metabolic acidosis. Oxalic acid, however, binds with calcium to form calcium oxalate crystals, which precipitate in the renal tubules, causing acute tubular necrosis and renal failure. These crystals may also be visible in the urine. Additionally, the metabolites cause cerebral edema and cardiac dysfunction.

Diagnosis: The Dual Gaps – Anion and Osmolal

A patient presenting with an unexplained altered mental status, visual complaints, or abdominal pain, often with a history of possible ingestion (e.g., antifreeze, windshield washer fluid, illicit alcohol), should prompt immediate consideration of toxic alcohols. Laboratory diagnosis relies on detecting two key gaps.

First, you will find a high anion gap metabolic acidosis. The anion gap is calculated as: $N{a}^{+}-(C{l}^{-}+HC{O}_3^{-})$. A normal gap is 8-12 mEq/L. The toxic metabolites (formic acid, glycolic acid) are unmeasured anions that accumulate, widening this gap. It's crucial to note that early in ingestion, before significant metabolism has occurred, the anion gap may be normal despite a large ingestion.

Second, you will find an elevated osmolal gap. The measured serum osmolality is compared to the calculated osmolality. The standard calculation is: $$(2\times Na)+(Glucose/18)+(BUN/2.8)$$. The difference (measured - calculated) is the osmolal gap, normally < 10 mOsm/kg. The parent alcohols, methanol and ethylene glycol, are osmotically active particles that are not in the calculation, creating a large gap. As the poisoning progresses and the parent alcohols are metabolized into acids, the osmolal gap falls while the anion gap rises. This inverse relationship is a classic hallmark.

Antidotal Therapy: Inhibition of Alcohol Dehydrogenase

The cornerstone of specific treatment is to halt the production of toxic metabolites by competitively inhibiting ADH. This gives the body time to excrete the unchanged, less harmful parent alcohol via the kidneys and lungs. There are two primary antidotes: fomepizole and ethanol.

Fomepizole (4-methylpyrazole) is now the first-line agent. It is a potent competitive inhibitor of ADH with a predictable pharmacokinetic profile and few side effects. Its administration does not cause CNS depression or hypoglycemia, unlike ethanol. The standard dosing is a loading dose of 15 mg/kg IV, followed by maintenance doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter. Dosing is adjusted during hemodialysis.

Ethanol can be used if fomepizole is unavailable. It works on the same principle: ADH has a much higher affinity for ethanol than for methanol or ethylene glycol. By maintaining a blood ethanol concentration of 100-150 mg/dL, you effectively "saturate" the enzyme, protecting the patient. However, ethanol therapy is fraught with challenges: it requires frequent level monitoring, can cause inebriation and hypoglycemia, and complicates ICU management.

Therapy with either antidote is continued until the toxic alcohol level is undetectable (<20 mg/dL) and the patient has a normal pH and no signs of toxicity.

Enhanced Elimination: The Role of Hemodialysis

Hemodialysis is a vital adjunctive treatment that serves two purposes: it rapidly removes both the parent alcohol and the toxic acids from the bloodstream, and it corrects severe metabolic acidosis and electrolyte abnormalities. Indications for urgent hemodialysis include:

• Severe metabolic acidosis (pH < 7.25-7.30)
• Deteriorating vital signs or end-organ damage (e.g., visual changes, renal failure)
• A toxic alcohol level > 50 mg/dL (though some guidelines use > 25-30 mg/dL for methanol given its high toxicity)
• Significant electrolyte imbalances refractory to medical management

During dialysis, the dosing interval for fomepizole must be shortened to every 4 hours because it is also dialyzable. Ethanol infusion rates must also be increased substantially during dialysis.

Supportive Care and Adjuncts

Alongside specific antidotes and dialysis, comprehensive supportive care is non-negotiable. This includes aggressive management of acidosis with intravenous sodium bicarbonate, especially if the pH is below 7.2. Bicarbonate therapy helps mitigate the toxic effects of formic and glycolic acid. For ethylene glycol poisoning, cofactor therapy with thiamine and pyridoxine is recommended. These vitamins may help shunt metabolism away from oxalic acid toward less harmful metabolites (glycine and alpha-hydroxy-beta-ketoadipate, respectively), though evidence for their efficacy is less robust than for ADH inhibition.

Common Pitfalls

1. Ruling out poisoning based on a normal early anion gap.

• Pitfall: A patient presents soon after ingestion. You check labs and find a normal anion gap, so you dismiss toxic alcohol poisoning.
• Correction: The anion gap only widens as the alcohol is metabolized to acid. An early, large ingestion will present with a high osmolal gap and a normal anion gap. Always calculate both gaps. The absence of an anion gap does not rule out a significant ingestion early on.

2. Delaying antidote administration while awaiting confirmatory levels.

• Pitfall: You suspect toxic alcohol poisoning but decide to wait for the serum methanol/ethylene glycol level, which may take hours, before starting fomepizole.
• Correction: This delay can be catastrophic. Treatment with fomepizole (or ethanol) is empiric and should be initiated immediately based on clinical history and the presence of an unexplained osmolal gap with or without an anion gap metabolic acidosis. Fomepizole is very safe and will not harm a patient who turns out not to have a toxic alcohol ingestion.

3. Misinterpreting the osmolal gap in the presence of other osmoles.

• Pitfall: A patient with diabetic ketoacidosis (DKA) and an elevated osmolal gap is assumed to have co-ingested toxic alcohol.
• Correction: Remember the osmolal gap calculation includes only sodium, glucose, and BUN. Ketonemia (from DKA or starvation) and severe lactic acidosis contribute unmeasured osmoles and can elevate the gap. While a markedly elevated gap (>25) is still suspicious, a moderate elevation in the setting of DKA alone is common. Clinical context and toxic alcohol levels are key.

4. Stopping antidote therapy prematurely.

• Pitfall: You stop the fomepizole infusion once the toxic alcohol level is below 20 mg/dL, but the patient is still acidotic.
• Correction: The endpoint for antidote therapy is twofold: a non-detectable toxic alcohol level AND resolution of acidosis (pH normal). Stopping while the patient is still acidotic risks rebound toxicity as remaining parent compound could be metabolized.

Summary

• Methanol and ethylene glycol cause toxicity primarily through metabolism by alcohol dehydrogenase (ADH) into formic acid (causing blindness and acidosis) and oxalic acid (causing renal failure), respectively.
• Diagnosis hinges on recognizing an anion gap metabolic acidosis paired with an elevated osmolal gap; early presentations may show only the osmolal gap.
• The specific antidote is fomepizole, a competitive ADH inhibitor that halts toxic metabolite formation; ethanol is an alternative if fomepizole is unavailable.
• Hemodialysis is indicated for severe acidosis (pH <7.25-7.30), end-organ damage, or high toxic alcohol levels (>50 mg/dL), and removes both parent compound and toxic acids.
• Treatment is empiric and must not be delayed for confirmatory levels; supportive care includes correcting acidosis with bicarbonate and, for ethylene glycol, providing cofactors (thiamine, pyridoxine).